TerminatedPhase 3NCT03809650

A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Studying Chronic thromboembolic pulmonary hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Actelion
Principal Investigator
Yoshinari Yokoyama, PhD
Actelion Japan
Intervention
macitentan 10 mg(drug)
Enrollment
9 enrolled
Eligibility
18-89 years · All sexes
Timeline
20192020

Study locations (23)

Collaborators

EPS Corporation · Imepro Inc. · General Laboratory, BML, Inc. · Mitsubishi Logistics Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03809650 on ClinicalTrials.gov

Other trials for Chronic thromboembolic pulmonary hypertension

Additional recruiting or active studies for the same condition.

See all trials for Chronic thromboembolic pulmonary hypertension

← Back to all trials